The GLP-1 revolution has fundamentally changed the landscape of pharmacological weight loss. What started with semaglutide producing 15% body weight reductions has escalated rapidly — tirzepatide pushed past 22%, and retatrutide is approaching 29% in Phase 3 data. For the first time, drug-based weight loss is rivaling the outcomes of bariatric surgery without the operating room.
But not all weight loss peptides work the same way, and maximum scale weight lost is not always the right metric. Some compounds are better for total fat mass reduction, others target visceral fat specifically, and a third category focuses on body recomposition — losing fat while preserving or gaining lean tissue. The right peptide depends on your specific goal, budget, and risk tolerance.
This guide ranks eight peptides by four criteria: clinical weight loss percentage from published trials, quality of evidence (Phase 3 RCTs rank highest), mechanism of action and target specificity, and monthly cost across different sourcing options. Every claim is linked to its source publication on PubMed.
Quick Rankings
All eight compounds ranked by maximum demonstrated weight loss from clinical or preclinical data.
| # | Peptide | Type | Max Loss | Status | Cost/mo |
|---|---|---|---|---|---|
| 1 | Retatrutide | Triple GLP-1/GIP/Glucagon Agonist | 28.7% | Phase 3 | $100-200 |
| 2 | Tirzepatide | Dual GLP-1/GIP Agonist | 22.5% | FDA Approved | $349-499 |
| 3 | Semaglutide | GLP-1 Receptor Agonist | 15% | FDA Approved | $349-1,350 |
| 4 | Tesamorelin | GHRH Analog (Visceral Fat) | 15.4% VAT | FDA Approved | $65-130 |
| 5 | AOD-9604 | GH Fragment (Fat Metabolism) | Moderate (preclinical) | Preclinical | $45-75 |
| 6 | MOTS-c | Mitochondrial-Derived Peptide | Moderate (preclinical) | Preclinical | $45-75 |
| 7 | CJC-1295 + Ipamorelin | GH Secretagogue Stack | Indirect (body composition) | Phase 2 | $80-150 |
| 8 | 5-Amino-1MQ | NNMT Inhibitor | Preclinical | Preclinical | $50-90 |
Compound Profiles
Detailed breakdown of each compound with clinical data, mechanism of action, and sourcing information.
#1 Retatrutide
Triple GLP-1/GIP/Glucagon AgonistRetatrutide is a triple-hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. This triple agonism represents the most aggressive pharmacological approach to weight loss currently in clinical development. The addition of glucagon receptor activity drives hepatic fat oxidation and thermogenesis beyond what dual GLP-1/GIP agonists can achieve alone.
In the Phase 2 trial published in the New England Journal of Medicine (PMID: 37366315), participants receiving the highest dose of retatrutide (12mg weekly) lost an average of 24.2% of their body weight at 48 weeks, with some cohorts approaching 28.7% in ongoing Phase 3 data. These numbers exceed every other weight loss compound tested in clinical trials to date.
Retatrutide is currently in Phase 3 trials sponsored by Eli Lilly. It is not yet FDA approved, but research-grade versions are available through peptide suppliers at significantly lower cost than branded GLP-1 drugs. The main side effects are gastrointestinal in nature, consistent with other incretin-based therapies.
#2 Tirzepatide
Dual GLP-1/GIP AgonistTirzepatide (brand name Zepbound for weight management, Mounjaro for diabetes) is a dual GLP-1 and GIP receptor agonist that has redefined expectations for pharmacological weight loss. By activating both incretin pathways, tirzepatide produces substantially greater weight reduction than GLP-1-only drugs like semaglutide.
The landmark SURMOUNT-1 trial (PMID: 35658024) demonstrated that tirzepatide at the highest dose (15mg weekly) produced 22.5% body weight loss at 72 weeks in adults with obesity. This was the first non-surgical intervention to approach the efficacy of bariatric surgery. Importantly, tirzepatide also showed significant improvements in cardiometabolic markers including blood pressure, triglycerides, and insulin sensitivity.
As an FDA-approved medication, tirzepatide is available by prescription under the brand names Zepbound (obesity) and Mounjaro (type 2 diabetes). Self-pay pricing through telehealth platforms ranges from $349-499 per month, while the list price without insurance is approximately $1,059 per month.
#3 Semaglutide
GLP-1 Receptor AgonistSemaglutide (brand names Wegovy for weight management, Ozempic for diabetes) is the GLP-1 receptor agonist that launched the modern weight loss revolution. It mimics the incretin hormone GLP-1, reducing appetite through central and peripheral mechanisms including delayed gastric emptying and direct hypothalamic signaling.
The STEP-1 trial (PMID: 33567185) showed that semaglutide 2.4mg weekly produced an average 14.9% body weight loss at 68 weeks compared to 2.4% with placebo. Subsequent trials in the STEP program confirmed these results across diverse populations. Semaglutide also carries cardiovascular benefit, with the SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events.
Semaglutide is the most widely prescribed weight loss medication globally. Wegovy is available by prescription with self-pay pricing from $349 per month through compounding pharmacies, up to $1,350 per month for brand-name product without insurance coverage. Generic availability is expected to reduce costs significantly within the next several years.
#4 Tesamorelin
GHRH Analog (Visceral Fat)Tesamorelin is a growth hormone-releasing hormone (GHRH) analog originally FDA-approved for HIV-associated lipodystrophy under the brand name Egrifta. Its primary mechanism involves stimulating pulsatile growth hormone release from the anterior pituitary, which preferentially mobilizes visceral adipose tissue (VAT) -- the metabolically dangerous fat surrounding internal organs.
Clinical trials demonstrated that tesamorelin reduced visceral adipose tissue by 15.4% over 26 weeks (PMID: 20534753), with concomitant improvements in triglycerides and IGF-1 levels. Unlike exogenous growth hormone, tesamorelin preserves the natural pulsatile release pattern and feedback mechanisms, resulting in a more physiological GH profile with fewer side effects.
Tesamorelin has become a cornerstone of body recomposition protocols due to its selective visceral fat reduction. It does not produce the same total body weight loss as GLP-1 agonists, but its ability to target the most metabolically dangerous fat depot makes it uniquely valuable. Research-grade tesamorelin is available at $65-130 per month, dramatically less than the $3,085 brand-name price.
#5 AOD-9604
GH Fragment (Fat Metabolism)AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 176-191. It was designed to retain the lipolytic (fat-burning) properties of growth hormone while eliminating its growth-promoting and diabetogenic effects. The fragment stimulates lipolysis and inhibits lipogenesis through a mechanism independent of the GH receptor.
Preclinical studies showed that AOD-9604 enhanced fat metabolism in obese animal models without affecting IGF-1 levels or glucose homeostasis (PMID: 11146367). However, human clinical trials produced underwhelming results, and the compound never achieved FDA approval for obesity. A Phase 2b trial showed modest weight loss that did not reach statistical significance against placebo at all doses tested.
Despite limited clinical evidence, AOD-9604 remains popular in the biohacking community due to its favorable safety profile and low cost. It is often stacked with other peptides rather than used as a standalone weight loss agent. Its primary value may be as an adjunct compound that contributes to fat oxidation without the hormonal disruption of full-length growth hormone.
#6 MOTS-c
Mitochondrial-Derived PeptideMOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide that acts as a metabolic regulator. It activates the AMPK pathway, which is the same metabolic switch targeted by metformin. MOTS-c enhances glucose uptake, improves insulin sensitivity, and promotes fatty acid oxidation at the cellular level.
Research published in Cell Metabolism (PMID: 25738459) demonstrated that MOTS-c prevented age-dependent and high-fat-diet-induced insulin resistance in mice. The peptide promoted metabolic homeostasis through AMPK activation and enhanced mitochondrial function. Circulating MOTS-c levels decline with age in humans, suggesting a potential role in age-related metabolic dysfunction.
MOTS-c is unique among weight loss peptides because it works through mitochondrial energy metabolism rather than appetite suppression or hormonal manipulation. This makes it potentially valuable for improving metabolic flexibility and exercise performance alongside fat loss. Human clinical data remains limited, so it is best considered an experimental adjunct rather than a primary weight loss agent.
#7 CJC-1295 + Ipamorelin
GH Secretagogue StackCJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog with a drug affinity complex (DAC) that extends its half-life to approximately 6-8 days. When combined with ipamorelin, a selective growth hormone secretagogue that mimics ghrelin, the two peptides produce synergistic and sustained increases in growth hormone and IGF-1 levels.
The CJC-1295 component was studied in Phase 2 clinical trials (PMID: 16352683) showing dose-dependent increases in GH and IGF-1 with a single injection sustaining elevated GH levels for up to 6 days. Ipamorelin is one of the most selective GH secretagogues available, stimulating GH release without significantly affecting cortisol, prolactin, or aldosterone levels.
The CJC-1295 plus ipamorelin combination does not produce direct weight loss comparable to GLP-1 agonists. Instead, it shifts body composition by increasing lean mass and promoting fat oxidation through elevated growth hormone signaling. This makes it better suited for recomposition goals rather than maximum scale weight reduction. The combination is widely used in anti-aging and performance optimization protocols.
#8 5-Amino-1MQ
NNMT Inhibitor5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is overexpressed in adipose tissue of obese individuals. NNMT regulates cellular energy expenditure through the NAD+ salvage pathway, and its inhibition has been shown to increase energy expenditure and shrink fat cells in preclinical models.
Research published in Biochemical Pharmacology (PMID: 32897102) demonstrated that NNMT inhibition with 5-Amino-1MQ reduced body weight and white adipose tissue mass in diet-induced obese mice without affecting food intake. The compound increased cellular NAD+ content and activated the sirtuin pathway, suggesting a mechanism that enhances metabolic rate rather than suppressing appetite.
5-Amino-1MQ represents a novel mechanism of action that is distinct from all other compounds on this list. It is typically taken orally as a capsule, which makes it more convenient than injectable peptides. However, all evidence is preclinical, and no human clinical trials have been completed. It is best considered a speculative addition to a comprehensive fat loss protocol.
Stacking Protocols
Combining peptides with complementary mechanisms can produce results beyond what any single compound achieves alone. These are the three most evidence-supported stacking approaches for fat loss.
The Shred Stack
Retatrutide + Tesamorelin
Combines the most potent weight loss compound in clinical development with targeted visceral fat reduction. Retatrutide drives overall caloric deficit through triple-receptor appetite suppression, while tesamorelin selectively mobilizes the deepest visceral fat through pulsatile GH release. This combination addresses both subcutaneous and visceral adipose tissue simultaneously.
Read the full Shred Stack guideVisceral Targeting Protocol
Semaglutide + Tesamorelin
Pairs the most proven and accessible GLP-1 agonist with tesamorelin for enhanced visceral fat reduction. Semaglutide provides reliable 15% total body weight loss while tesamorelin adds preferential reduction of the metabolically dangerous visceral fat depot. Suitable for individuals who want FDA-approved options with visceral targeting.
GH-Based Recomposition
CJC-1295 + Ipamorelin
A growth hormone secretagogue stack for individuals focused on body recomposition rather than maximum scale weight loss. The sustained GH elevation promotes lean mass retention and fat oxidation simultaneously. Best suited for active individuals who are training consistently and want to improve body composition metrics rather than total body weight.
How to Choose
The best peptide depends on your specific goal. Here is a decision framework based on the most common objectives.
Maximum fat loss
Retatrutide or Tirzepatide
Highest clinical weight loss percentages
FDA-approved options
Semaglutide (Wegovy) or Tirzepatide (Zepbound)
Proven safety profile, physician-supervised
Visceral fat specifically
Tesamorelin
Selective visceral adipose tissue reduction
Body recomposition
Retatrutide + Tesamorelin
Fat loss with lean mass preservation
Budget-friendly
AOD-9604 or MOTS-c
$45-75/month, less clinical evidence
GH-based approach
CJC-1295 + Ipamorelin
Indirect fat loss through GH elevation
Cost Comparison
Monthly costs for the four compounds with the strongest clinical evidence, compared across sourcing options.
| Compound | Research Chem | Brand / Self-Pay | Brand / List |
|---|---|---|---|
| Retatrutide | $100-200 | N/A (not approved) | N/A |
| Tirzepatide | N/A | $349-499 (Zepbound) | $1,059 |
| Semaglutide | N/A | $349 (Wegovy) | $1,350 |
| Tesamorelin | $65-130 | $3,085 (Egrifta) | $3,085 |
Cost note: Research-grade peptides are not FDA-regulated and carry risks including unknown purity and contamination. FDA-approved brands (Wegovy, Zepbound) provide verified pharmaceutical-grade product with physician oversight. Self-pay prices reflect telehealth compounding pharmacy pricing as of April 2026.
Frequently Asked Questions
Disclaimer: This content is for research and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Several compounds listed here are not FDA-approved for weight loss. Use of research-grade peptides carries inherent risks including contamination, inaccurate dosing, and unknown long-term effects. Always consult a qualified healthcare provider before using any weight loss compound. BodyHackGuide does not sell, supply, or endorse the purchase of any controlled or investigational substance.
Last updated: April 13, 2026 · Written by BioChonch · BodyHackGuide Research Team
Independent researcher and founder of BodyHackGuide. Obsessed with evidence-based biohacking, peptide science, and nootropic protocols. Every recommendation is backed by PubMed citations and real-world testing.
Was this page helpful?
